Table 3. Open in new tab Pharmacokinetic...

Metabolite	C_max (ng/mL)	t_max (h)	t_1/2 (h)	AUC₁₂ (ng·h/mL)	AUC_∞ (ng·h/mL)	CL/F (L/h)	V_z/F (L)
LSD and placebo
LSD	2.13 ± 0.72	2.0 ± 0.8	4.2 ± 1.6	13.8 ± 5.9	17 ± 9	7.2 ± 2.9	39 ± 10
	(1.27–4.26)	(0.5–3.5)	(2.6–8.9)	(6.7–30.8)	(7–43)	(2.3–14.2)	(20–52)
O-H-LSD	0.15 ± 0.44	5.5 ± 1.8	8.3 ± 3.1	1.3 ± 0.4	2.4 ± 0.8	47.4 ± 20.9	532 ± 219
	(0.06–0.24)	(2.5–9.0)	(4.1–14.9)	(0.6–2.2)	(0.8–3.6)	(27.4–123.5)	(231–1211)
LSD and ketanserin
LSD	2.18 ± 0.63	2.0 ± 0.8	4.1 ± 1.1	13.7 ± 4.3	16.3 ± 6.1	7.0 ± 2.7	39 ± 11
	(1.17–3.19)	(1.0–4.0)	(2.9–7.0)	(7.0–20.7)	(8.1–29.5)	(3.4–12.3)	(24–65)
O-H-LSD	0.15 ± 0.04	4.7 ± 1.5	9.0 ± 3.5	1.3 ± 0.3	2.5 ± 0.8	45.2 ± 16.8	549 ± 172
	(0.08–0.23)	(3.0–9.0)	(5.5–20.9)	(0.7–2.1)	(1.0–4.3)	(23.1–101.5)	(262–964)
Ketanserin	129 ± 46	2.3 ± 1.0	3.5 ± 0.6	442 ± 140	509 ± 157	86 ± 28	442 ± 198
	(44–203)	(1.0–5.0)	(2.5–4.9)	(184–753)	(245–893)	(45–163)	(254–1145)

Metabolite

C_max (ng/mL)

t_max (h)

t_1/2 (h)

AUC₁₂ (ng·h/mL)

AUC_∞ (ng·h/mL)

CL/F (L/h)

V_z/F (L)

LSD and placebo

LSD

2.13 ± 0.72

2.0 ± 0.8

4.2 ± 1.6

13.8 ± 5.9

17 ± 9

7.2 ± 2.9

39 ± 10

(1.27–4.26)

(0.5–3.5)

(2.6–8.9)

(6.7–30.8)

(7–43)

(2.3–14.2)

(20–52)

O-H-LSD

0.15 ± 0.44

5.5 ± 1.8

8.3 ± 3.1

1.3 ± 0.4

2.4 ± 0.8

47.4 ± 20.9

532 ± 219

(0.06–0.24)

(2.5–9.0)

(4.1–14.9)

(0.6–2.2)

(0.8–3.6)

(27.4–123.5)

(231–1211)

LSD and ketanserin

LSD

2.18 ± 0.63

2.0 ± 0.8

4.1 ± 1.1

13.7 ± 4.3

16.3 ± 6.1

7.0 ± 2.7

39 ± 11

(1.17–3.19)

(1.0–4.0)

(2.9–7.0)

(7.0–20.7)

(8.1–29.5)

(3.4–12.3)

(24–65)

O-H-LSD

0.15 ± 0.04

4.7 ± 1.5

9.0 ± 3.5

1.3 ± 0.3

2.5 ± 0.8

45.2 ± 16.8

549 ± 172

(0.08–0.23)

(3.0–9.0)

(5.5–20.9)

(0.7–2.1)

(1.0–4.3)

(23.1–101.5)

(262–964)

Ketanserin

129 ± 46

2.3 ± 1.0

3.5 ± 0.6

442 ± 140

509 ± 157

86 ± 28

442 ± 198

(44–203)

(1.0–5.0)

(2.5–4.9)

(184–753)

(245–893)

(45–163)

(254–1145)

Metabolite	C_max (ng/mL)	t_max (h)	t_1/2 (h)	AUC₁₂ (ng·h/mL)	AUC_∞ (ng·h/mL)	CL/F (L/h)	V_z/F (L)
LSD and placebo
LSD	2.13 ± 0.72	2.0 ± 0.8	4.2 ± 1.6	13.8 ± 5.9	17 ± 9	7.2 ± 2.9	39 ± 10
	(1.27–4.26)	(0.5–3.5)	(2.6–8.9)	(6.7–30.8)	(7–43)	(2.3–14.2)	(20–52)
O-H-LSD	0.15 ± 0.44	5.5 ± 1.8	8.3 ± 3.1	1.3 ± 0.4	2.4 ± 0.8	47.4 ± 20.9	532 ± 219
	(0.06–0.24)	(2.5–9.0)	(4.1–14.9)	(0.6–2.2)	(0.8–3.6)	(27.4–123.5)	(231–1211)
LSD and ketanserin
LSD	2.18 ± 0.63	2.0 ± 0.8	4.1 ± 1.1	13.7 ± 4.3	16.3 ± 6.1	7.0 ± 2.7	39 ± 11
	(1.17–3.19)	(1.0–4.0)	(2.9–7.0)	(7.0–20.7)	(8.1–29.5)	(3.4–12.3)	(24–65)
O-H-LSD	0.15 ± 0.04	4.7 ± 1.5	9.0 ± 3.5	1.3 ± 0.3	2.5 ± 0.8	45.2 ± 16.8	549 ± 172
	(0.08–0.23)	(3.0–9.0)	(5.5–20.9)	(0.7–2.1)	(1.0–4.3)	(23.1–101.5)	(262–964)
Ketanserin	129 ± 46	2.3 ± 1.0	3.5 ± 0.6	442 ± 140	509 ± 157	86 ± 28	442 ± 198
	(44–203)	(1.0–5.0)	(2.5–4.9)	(184–753)	(245–893)	(45–163)	(254–1145)

Table 3.

Open in new tab

Pharmacokinetic Parameters

Metabolite	C_max (ng/mL)	t_max (h)	t_1/2 (h)	AUC₁₂ (ng·h/mL)	AUC_∞ (ng·h/mL)	CL/F (L/h)	V_z/F (L)
LSD and placebo
LSD	2.13 ± 0.72	2.0 ± 0.8	4.2 ± 1.6	13.8 ± 5.9	17 ± 9	7.2 ± 2.9	39 ± 10
	(1.27–4.26)	(0.5–3.5)	(2.6–8.9)	(6.7–30.8)	(7–43)	(2.3–14.2)	(20–52)
O-H-LSD	0.15 ± 0.44	5.5 ± 1.8	8.3 ± 3.1	1.3 ± 0.4	2.4 ± 0.8	47.4 ± 20.9	532 ± 219
	(0.06–0.24)	(2.5–9.0)	(4.1–14.9)	(0.6–2.2)	(0.8–3.6)	(27.4–123.5)	(231–1211)
LSD and ketanserin
LSD	2.18 ± 0.63	2.0 ± 0.8	4.1 ± 1.1	13.7 ± 4.3	16.3 ± 6.1	7.0 ± 2.7	39 ± 11
	(1.17–3.19)	(1.0–4.0)	(2.9–7.0)	(7.0–20.7)	(8.1–29.5)	(3.4–12.3)	(24–65)
O-H-LSD	0.15 ± 0.04	4.7 ± 1.5	9.0 ± 3.5	1.3 ± 0.3	2.5 ± 0.8	45.2 ± 16.8	549 ± 172
	(0.08–0.23)	(3.0–9.0)	(5.5–20.9)	(0.7–2.1)	(1.0–4.3)	(23.1–101.5)	(262–964)
Ketanserin	129 ± 46	2.3 ± 1.0	3.5 ± 0.6	442 ± 140	509 ± 157	86 ± 28	442 ± 198
	(44–203)	(1.0–5.0)	(2.5–4.9)	(184–753)	(245–893)	(45–163)	(254–1145)

Metabolite	C_max (ng/mL)	t_max (h)	t_1/2 (h)	AUC₁₂ (ng·h/mL)	AUC_∞ (ng·h/mL)	CL/F (L/h)	V_z/F (L)
LSD and placebo
LSD	2.13 ± 0.72	2.0 ± 0.8	4.2 ± 1.6	13.8 ± 5.9	17 ± 9	7.2 ± 2.9	39 ± 10
	(1.27–4.26)	(0.5–3.5)	(2.6–8.9)	(6.7–30.8)	(7–43)	(2.3–14.2)	(20–52)
O-H-LSD	0.15 ± 0.44	5.5 ± 1.8	8.3 ± 3.1	1.3 ± 0.4	2.4 ± 0.8	47.4 ± 20.9	532 ± 219
	(0.06–0.24)	(2.5–9.0)	(4.1–14.9)	(0.6–2.2)	(0.8–3.6)	(27.4–123.5)	(231–1211)
LSD and ketanserin
LSD	2.18 ± 0.63	2.0 ± 0.8	4.1 ± 1.1	13.7 ± 4.3	16.3 ± 6.1	7.0 ± 2.7	39 ± 11
	(1.17–3.19)	(1.0–4.0)	(2.9–7.0)	(7.0–20.7)	(8.1–29.5)	(3.4–12.3)	(24–65)
O-H-LSD	0.15 ± 0.04	4.7 ± 1.5	9.0 ± 3.5	1.3 ± 0.3	2.5 ± 0.8	45.2 ± 16.8	549 ± 172
	(0.08–0.23)	(3.0–9.0)	(5.5–20.9)	(0.7–2.1)	(1.0–4.3)	(23.1–101.5)	(262–964)
Ketanserin	129 ± 46	2.3 ± 1.0	3.5 ± 0.6	442 ± 140	509 ± 157	86 ± 28	442 ± 198
	(44–203)	(1.0–5.0)	(2.5–4.9)	(184–753)	(245–893)	(45–163)	(254–1145)

Abbreviations: AUC = area under the plasma concentration-time curve; AUC_∞ = AUC from time zero to infinity; AUC₁₂ = from time 0-12 h; CL/F = apparent total clearance; C_max = maximum observed plasma concentration; O-H-LSD = 2-oxo-3-hydroxy LSD; T_1/2 = plasma half-life; T_max = time to reach C_max; V_z/F = apparent volume of distribution. n = 24.

Values are mean ± SD (range).

This Feature Is Available To Subscribers Only